Eli Lilly's Mounjaro (Tirzepatide), a dual GIP and GLP-1 receptor agonist, has launched in India, generating buzz as a weight ...

Amy Schumer has provided fans with a comical update on her weight loss journey. The I Feel Pretty star said she tried Ozempic ...

Savvy pharma-stock investors know that an oral GLP-1 drug from Novo Nordisk called Rybelsus has been on the market as a ...

A once-weekly dose of tirzepatide (Mounjaro) can lead to significant, sustained weight loss for up to 3 years in adults with ...

"Women coming off weight loss injections in midlife need to be particularly strategic about their approach," Rachael adds. "The hormonal shifts of midlife can reduce muscle protein synthesis by up to ...

But the popular injection is seeing new competition with Mounjaro, and now a daily pill which could help patients lose 16 ...

Novo Nordisk's stocks face YTD struggles due to trial results and tariffs, but strong fundamentals and outlook justify a Buy.

The first GLP-1 weight-loss pill is a step closer to hitting the market. Eli Lilly said its experimental pill met its goals ...

Researchers at Mass General Brigham found that by December 2023, over one-third of all new prescriptions for type 2 diabetes were for GLP-1 receptor agonists, such as semaglutide or tirzepatide. New ...

Lilly shares are up 14.2% in response to the news, while shares of its rivals in the GLP-1 weight loss market, Novo Nordisk ( ...

A daily pill from drugmaker Eli Lilly has shown safety results comparable to the leading injectable GLP-1 drugs Mounjaro and ...

A daily weight loss pill being tested by Eli Lilly could work as well as its GLP-1 injection counterparts like Ozempic, ...